BG102355A - Method for the stimulation of cellular mediated immune response by the orientation of a specific genetic immunization - Google Patents

Method for the stimulation of cellular mediated immune response by the orientation of a specific genetic immunization

Info

Publication number
BG102355A
BG102355A BG102355A BG10235598A BG102355A BG 102355 A BG102355 A BG 102355A BG 102355 A BG102355 A BG 102355A BG 10235598 A BG10235598 A BG 10235598A BG 102355 A BG102355 A BG 102355A
Authority
BG
Bulgaria
Prior art keywords
stimulation
orientation
immune response
mediated immune
antigene
Prior art date
Application number
BG102355A
Other languages
Bulgarian (bg)
English (en)
Inventor
Louis FALO
Kenneth Rock
Original Assignee
University Of Pitisburgh Of The Commonwealth System Of Highe
Dana-Faber Cancer Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Pitisburgh Of The Commonwealth System Of Highe, Dana-Faber Cancer Institute filed Critical University Of Pitisburgh Of The Commonwealth System Of Highe
Publication of BG102355A publication Critical patent/BG102355A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BG102355A 1995-09-28 1998-03-26 Method for the stimulation of cellular mediated immune response by the orientation of a specific genetic immunization BG102355A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53555695A 1995-09-28 1995-09-28
PCT/US1996/015728 WO1997011605A1 (en) 1995-09-28 1996-09-27 Stimulation of cell-mediated immune responses by targeted particulate genetic immunization

Publications (1)

Publication Number Publication Date
BG102355A true BG102355A (en) 1999-04-30

Family

ID=24134735

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102355A BG102355A (en) 1995-09-28 1998-03-26 Method for the stimulation of cellular mediated immune response by the orientation of a specific genetic immunization

Country Status (15)

Country Link
EP (1) EP0863704A4 (xx)
JP (1) JPH11512724A (xx)
KR (1) KR19990063672A (xx)
CN (1) CN1201369A (xx)
AU (1) AU716497B2 (xx)
BG (1) BG102355A (xx)
CA (1) CA2233278A1 (xx)
CZ (1) CZ92998A3 (xx)
HU (1) HUP9802651A3 (xx)
NO (1) NO981386L (xx)
NZ (1) NZ319891A (xx)
PL (1) PL325953A1 (xx)
SK (1) SK40198A3 (xx)
TR (1) TR199800573T2 (xx)
WO (1) WO1997011605A1 (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110898A (en) * 1996-05-24 2000-08-29 University Of Maryland, Baltimore DNA vaccines for eliciting a mucosal immune response
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6287569B1 (en) * 1997-04-10 2001-09-11 The Regents Of The University Of California Vaccines with enhanced intracellular processing
AU3291099A (en) * 1998-02-11 1999-08-30 Maxygen, Inc. Genetic vaccine vector engineering
CA2358385C (en) 1998-12-31 2013-08-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
JP2002542264A (ja) * 1999-04-21 2002-12-10 パウダージェクト ヴァクシンズ，インコーポレイテッド 核酸による免疫化
EP1372704B1 (en) * 2001-03-30 2008-10-15 Ghc Research Development Corporation Monocyte-specific particulate delivery vehicle
WO2003004620A2 (en) 2001-07-05 2003-01-16 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US11529414B2 (en) 2020-06-23 2022-12-20 Orbis Health Solutions, Llc Viral vaccines for in vivo expression of a nucleic acid encoding an immunogenic peptide and methods of using the same

Also Published As

Publication number Publication date
PL325953A1 (en) 1998-08-17
HUP9802651A3 (en) 2001-08-28
CZ92998A3 (cs) 1998-09-16
NZ319891A (en) 1999-01-28
KR19990063672A (ko) 1999-07-26
NO981386L (no) 1998-05-28
AU7251596A (en) 1997-04-17
EP0863704A1 (en) 1998-09-16
WO1997011605A1 (en) 1997-04-03
TR199800573T2 (xx) 1998-07-21
JPH11512724A (ja) 1999-11-02
HUP9802651A2 (hu) 1999-02-01
NO981386D0 (no) 1998-03-26
EP0863704A4 (en) 2003-09-10
CA2233278A1 (en) 1997-04-03
AU716497B2 (en) 2000-02-24
SK40198A3 (en) 1998-11-04
CN1201369A (zh) 1998-12-09

Similar Documents

Publication Publication Date Title
FR19C1020I1 (fr) Nouvelles molecules b7-4 et leurs utilisations
PT871482E (pt) Vesiculovírus recombinantes e suas utilizações
IE883612L (en) Vectors and compounds for direct expression of activated human protein c
MX9702714A (es) Produccion de peptidos en plantas como fusiones de proteinas con revestimiento viral.
WO1990000594A3 (en) Recombinant mycobacterial expression vehicles and uses therefor
DK0663010T3 (da) Fremgangsmåde til forøgelse af sekretion af overudtrykte proteiner
WO2000075336A3 (fr) Fragment proteiques polyepitopiques des proteines e6 et e7 de hpv, leur obtention et leurs utilisations notamment en vaccination
ES2009907A6 (es) Procedimiento para detectar en sangre humana la presencia de anticuerpos frente al virus sida.
NZ331651A (en) BSW17 peptide immunogens for vaccination against and treatment of allergy
NO970740L (no) Glutamat reseptor
BG102355A (en) Method for the stimulation of cellular mediated immune response by the orientation of a specific genetic immunization
MX9708791A (es) Gen de ataxia-telangiectasia y su organizacion genomica.
HUT41442A (en) Recombinant process for preparing serine protease inhibitors and dna sequences applicable in the process
DE69831500T2 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
AU8258591A (en) Human mk gene and protein sequence
WO1989007144A3 (en) High yield protein production system
AU1322692A (en) Method for the in vitro production of protein from a dna sequence without cloning
AU1060397A (en) High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein
MY105080A (en) Heat-labile toxin b subunit fusion proteins.
ZA985393B (en) Clostridium perfringens vaccine
NZ238833A (en) Equine herpesvirus-4 gh or gc polypeptides, nucleic acids encoding them and vaccines therefrom
UA43308C2 (uk) Спосіб надання рослині резистентності до склеротиніозу
ES8306177A1 (es) Un metodo de proporcionar una muestra de un gen fusionado que codifica un polipeptido eucariotico o procariotico deseado.
WO1990006943A3 (de) Neue tnf-peptide
KR900702010A (ko) 루시페라아제, 그것을 코우드 하는 유전자 및 루시페라아제의 생산방법